H.C. Wainwright reiterates Buy on Rezolute stock, $10 target
H.C. Wainwright reiterated a Buy rating and $10 price target for Rezolute Inc. (RZLT) after FDA feedback on its ersodetug candidate. The stock trades at $4.33, with analysts citing regulatory developments and clinical trial progress. Rezolute plans to discuss both its congenital hyperinsulinism and tumor hyperinsulinism programs with the FDA, with upLIFT trial results expected by year-end 2026. The company has a strong balance sheet, according to InvestingPro Tips.
How this was made
The 30-second read
Why it matters
The FDA's recommendation for a pre‑BLA meeting signals progress but also highlights remaining data requirements, influencing short‑term price dynamics.
Market read
Analyst upgrades combined with FDA regulatory feedback create a fresh catalyst for RZLT.
What to watch
The upcoming upLIFT tumor readout by year‑end could alter the upside narrative.
Background
Rezolute is a clinical‑stage biotech developing therapies for congenital hyperinsulinism and tumor‑associated hyperinsulinism.
Ticker impact
H.C. Wainwright reiterated a Buy rating and raised the price target to $10 after the FDA recommended a pre‑BLA meeting for Rezolute's ersodetug candidate.
likely upward pressure as investors price in the higher target and regulatory progress
The new FDA recommendation and multiple analyst target hikes provide fresh, material information that could drive the stock higher.
Market effects
Positive regulatory feedback may lift sentiment across small‑cap biotech peers.
Limited to U.S. biotech market.
Minimal global impact beyond sector.
Counterpoint
If the FDA later demands additional data, the stock could face a sharp correction.
Key entities
- companyRezolute Inc.
Biotech firm developing ersodetug and upLIFT programs.
- analystH.C. Wainwright
Equity research firm that raised its price target.
